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Abstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection is not uncommon as a result of
similar routes of infection. Patients who are coinfected represent a unique group with diverse
serologic profiles. Combined chronic hepatitis B and C leads to more severe liver disease and an
increased risk of hepatocellular carcinoma. Furthermore, coinfected patients represent a treatment
challenge. No standard recommendations exist for treatment of viral hepatitis due to dual HBV/
HCV infection, and therefore treatment must be individualized based on patient variables such as
serologic and virologic profiles, patient's prior exposure to antiviral treatment, and the presence
of other parenterally transmitted viruses such as hepatitis D virus and human immunodeficiency
virus. The natural history and treatment of patients with HBV and HCV coinfection is reviewed.
Introduction
Hepatitis B and hepatitis C viruses are the most common
causes of chronic liver disease worldwide. Acute infection
with hepatitis B virus (HBV) or hepatitis C virus (HCV)
may result in chronic infection, which occurs at a high rate
in infants infected with HBV and the majority of individ-
uals infected with HCV. Chronic HBV and/or HCV infec-
tion can progress to cirrhosis and be complicated by
hepatocellular carcinoma (HCC). Coinfection with both
viruses can occur because of shared routes of infection.
Patients with dual HBV and HCV infection have more
severe liver disease, and are at an increased risk for pro-
gression to HCC [1-4]. Coinfected patients represent a
diverse group with various viral replication and immunity
profiles. Because of their distinct clinical course and heter-
ogeneity, identification of patients who are candidates for
therapy and selection of the optimal antiviral therapy is a
challenge for clinicians. Herein we review the natural his-
tory of HBV/HCV coinfection, current understanding of
the interactions between these hepatotropic viruses, and
the limited literature on treatment of coinfected patients.
Epidemiology
Approximately 350 million people are infected with HBV
worldwide [5], and the World Health Organization esti-
mates that approximately 170 million people are infected
with HCV [6]. The exact number of patients infected with
both HCV and HBV is unknown. One Eastern European
study found a rate of dual infection in 0.68% of a ran-
domly selected healthy population of over 2200
individuals [7]. In patients with chronic hepatitis B, esti-
mates of the rates of HCV coinfection vary from 9% to
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30%, depending on the geographic region [8]. One Italian
study found that rates of dual infection increased with
age, and was more common in patients over 50 years of
age [9]. These numbers may underestimate the true
number of patients with both viral infections because no
large-scale studies have been performed, and there is a
well-described phenomenon of "serologically silent"
occult HBV infection (i.e. patients with negative hepatitis
B surface antigen [HBsAg] but detectable serum HBV
DNA) in patients with chronic hepatitis C [10].
Screening for Coinfection
Persons with a first episode of acute hepatitis should be
screened for all viral causes including HBV and HCV.
Some patients may be inoculated with both viruses simul-
taneously and will present with acute hepatitis due to
both viruses. In addition, HBV superinfection in patients
with chronic hepatitis C, and HCV superinfection in
patients with chronic hepatitis B have both been reported
[11-13]. Therefore, episodes of acute hepatitis in patients
with known chronic HBV or HCV infection, especially
those with ongoing risk behavior for infection with the
alternative virus such as injection drug users, should raise
suspicion and prompt screening for superinfection. In
addition, as will be described below, silent or occult HBV
infection in patients with chronic hepatitis C may alter
patients' clinical course and response to therapy [14,15].
However, this phenomenon requires further study regard-
ing its clinical significance before routine screening of
HCV patients for HBV DNA can be recommended.
Interaction of Hepatitis Viruses
Several studies have shown that the HBV and HCV interact
with each other and affect immune responses. HCV infec-
tion can suppress HBV replication, as demonstrated by
studies showing that patients with chronic hepatitis B
who are coinfected with HCV have lower HBV DNA levels,
decreased activity of HBV DNA polymerase, and
decreased expression of HBsAg and hepatitis B core anti-
gen in the liver [16-18]. Furthermore, patients with
chronic HBV infection who become superinfected with
HCV can undergo seroconversion of hepatitis B e antigen
(HBeAg) and HBsAg to respective antibodies [19-21].
Sheen et al. [22] conducted a longitudinal follow-up
study of a large series of HBV infected patients and found
that the annual incidence of HBsAg seroconversion was
2.08% in coinfected patients compared to 0.43% in
patients with HBV monoinfection, and a subsequent
study confirmed these results [23]. Several mechanisms of
replicative interference of HBV by HCV have been pro-
posed. Shih et al. implicated the hepatitis C core protein
in suppression of HBV [24]. A subsequent study found
that the hepatitis C core protein suppressed HBV enhancer
activity, thereby affecting transcription [25]. This inhibi-
tory effect appears to be more pronounced with HCV gen-
otype 1 both in vitro and in vivo [25,26].
Several authors have reported that HBV can reciprocally
inhibit HCV replication as well [27,28]. Specifically, HBV
DNA replication has been shown to correlate with
decreased HCV RNA levels in coinfected patients [29]. In
one Italian study, coinfected patients had a rate of HCV
RNA clearance of 71% compared to 14% with HCV
monoinfection [26]. HBV replication in coinfected indi-
viduals may result in more liver inflammation, as demon-
strated by studies in which HBV replication correlated
with elevated ALT levels, while HCV replication did not
[28,30,31]. Furthermore, coinfected patients have been
demonstrated to have lower levels of both HBV DNA and
HCV RNA than corresponding monoinfected controls,
indicating that concurrent suppression of both viruses by
the other virus can also occur. [32].
Overall, the available evidence demonstrates that both
viruses can inhibit each other simultaneously; either virus
can play a dominant role; both viruses have the ability to
induce seroconversion of the other; the chronology of
infection has a role in determining the dominant virus;
and HBV and HCV can alternate their dominance [8].
However, the overall dominant effect appears to be HCV
suppression of HBV [11,32,33].
Clinical Scenarios
Different scenarios of infection have been described with
dual infection with HBV and HCV including acute dual
viral hepatitis, occult HBV coinfection of chronic hepatitis
C, and superinfection by either virus in patients with pre-
existing chronic hepatitis due to the alternative virus. In
addition, coinfected patients are often found to have evi-
dence of both HBV and HCV infection without a clear
chronology of infection. In areas with high endemic rates
of HBV infection due to vertical transmission, coinfection
can generally be assumed to be due to HCV superinfec-
tion. In other geographic areas, the sequence of infections
is less clear. Acute coinfection or superinfection with
either virus can lead to fulminant hepatitis, chronic hepa-
titis, cirrhosis and HCC (Figure 1).
Acute Hepatitis due to Dual Infection
Few studies have been reported on simultaneous acute
hepatitis with HBV and HCV, but it appears that HBV and
HCV interact in acute infections similar to their interac-
tions in chronic infection. Simultaneous coinfection via
an accidental needle stick that resulted in acute hepatitis
was first described by Liaw in 1982 [34]. The diagnosis of
HBV infection was delayed for 6 weeks, possibly related to
HCV interference. Simultaneous coinfection resulting in
acute post-transfusion hepatitis has also been described
[35]. Mimms et al [36]. studied patients with concurrentAnnals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
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acute infection with HBV and HCV compared to those
with acute HBV alone, and reported decreased ALT levels,
delayed appearance of HBsAg, and a shorter duration of
hepatitis B surface antigenemia in coinfected patients
compared to controls, suggesting HCV suppression of
HBV activity.
Occult Hepatitis B Infection
Several reports have described the entity of occult or sero-
logically silent HBV infection, particularly as it relates to
treatment outcomes [10,14]. Occult HBV infection refers
to patients who have low levels of circulating HBV DNA,
but who lack both circulating antigens and their corre-
sponding antibodies (i.e. HBsAg, HBeAg, hepatitis B sur-
face antibody [anti-HBs] and hepatitis B e antibody [anti-
HBe]). Such patients have been shown to have more
severe liver disease [37]. One study found that 33% of
patients with chronic hepatitis C and occult HBV infection
had cirrhosis, compared to 19% of patients with chronic
HCV infection without detectable HBV DNA [38]. Occult
HBV may also be associated with more liver inflamma-
tion, greater histological activity of hepatitis, and higher
ALT levels [14]. The effect of serologically silent infections
on response to treatment will be discussed below.
Hepatitis C Superinfection
In areas of high prevalence of HBV infection such as Asian
countries, the phenomenon of HCV superinfection is well
described [11,13]. Superinfection with HCV can result in
suppression of HBV replication, as well as termination of
Infectious scenarios and treatment window for patients coinfected with hepatitis B and hepatitis C viruses Figure 1
Infectious scenarios and treatment window for patients coinfected with hepatitis B and hepatitis C viruses. HBV = hepatitis B 
virus, HCV = hepatitis C virus.
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the HBsAg carriage [11]. There is one case report of acute
HCV superinfection resulting in HBeAg seroconversion as
well as clearance of HBsAg [20]. After superinfection and
seroconversion of HBsAg, HCV infection may persist and
result in continued chronic hepatitis [19]. Besides its viral
interaction with HBV, HCV superinfection can result in
more severe liver disease and an increased risk of fulmi-
nant hepatitis [39]. The mortality rate of HCV superinfec-
tion in chronic hepatitis B patients may be as high as 10%
[11].
Hepatitis B Superinfection
Superinfection with HBV in patients with chronic hepati-
tis C is less common. Liaw et al. reported a series of 2
patients with chronic hepatitis C with documented HBV
superinfection (positive IgM anti-HBc) [12]. One 82-year-
old patient who was positive for both HBV DNA and HCV
RNA on admission died of fulminant hepatic failure. The
second patient was HBsAg positive, but HBV DNA nega-
tive. She subsequently recovered from acute hepatitis with
normalization of ALT and seroconversion of HBsAg, as
well as disappearance of anti-HCV antibody, indicating a
possible suppressive role of HBV on HCV infection. It is
difficult to draw conclusions from this limited report, but
it is reasonable to assume that there may be an increased
risk of fulminant hepatitis with HBV superinfection, and
that those who recover are at risk for chronic coinfection.
The clearance of anti-HCV in this case suggests that super-
infection may allow HBV to play the dominant role in
suppression of HCV.
Fulminant Hepatitis
Several studies have addressed the role of coinfection with
HBV and HCV in fulminant hepatitis. Chu et al. [39] con-
ducted a prospective study of patients admitted with acute
hepatitis C in Taiwan. Eleven patients had fulminant hep-
atitis, and of these, 23% had underlying chronic HBV
infection, compared to 2.9% for patients without fulmi-
nant hepatitis. This corresponded to an odds ratio (OR)
for chronic HBV patients developing fulminant hepatitis
with HCV superinfection of 10.2 (95% confidence inter-
val 4.7–21.9, p < 0.01). A French study of 40 patients with
fulminant and subfulminant hepatitis found that 5 of 40
patients (12.5%) had acute coinfection with HBV and
HCV and 3 of 40 (7.5%) had superinfection of HCV [40].
Another Taiwanese study of 25 subfulminant and fulmi-
nant hepatitis cases found similar rates of coinfection
(9.4%) and HCV superinfection of chronic hepatitis B
(3.1%) [41]. These studies suggest an increased risk of ful-
Table 1: AASLD Recommendations for Treatment of Chronic Hepatitis B
HBeAg HBV DNA ALT Treatment Strategy
++ ≤2 × ULN Low efficacy with current treatment.
Observe; consider treatment when ALT becomes elevated
+ + >2 × ULN IFN-α, LAM, or ADV may be used as initial therapy
End point of treatment = seroconversion from HbeAg to anti-Hbe Duration of therapy:
• IFN-α: 16 weeks
• LAM: minimum 1 year, continue for 3–6 months after HbeAg seroconversion
• ADV: minimum 1 year
IFN-α nonresponders/contraindications to IFN-α → LAM or ADV
LAM resistance → ADV
- + >2 × ULN IFN-α, LAM or ADV may be used as initial therapy, IFN-α or ADV is preferred
End point of treatment = sustained normalization of ALT and undetectable HBV DNA by PCR assay
Duration of therapy:
• IFN-α: 1 year
• LAM: > 1 year
• ADV: > 1 year
IFN-α nonresponders/contraindications to IFN-α → LAM or ADV
LAM resistance → ADV
-- ≤2 × ULN No treatment required
± + Cirrhosis Compensated: LAM or ADV
Decompensated: LAM (or ADV); Refer for liver transplant. IFN-α contraindicated.
± - Cirrhosis Compensated: Observe
Decompensated: Refer for liver transplant
*HBV DNA > 105. Abbreviations: HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; ALT: alanine aminotransferase; ULN: upper limit of normal; 
IFN-α: interferon alfa; LAM: lamivudine; ADV: adefovir; PCR: polymerase chain reaction. Source: Lok AS, McMahon BJ. Chronic hepatitis B: update 
of recommendations. Hepatology 2004;39:857-61.Annals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
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minant hepatitis with HCV and HBV coinfection and
superinfection.
Chronic Hepatitis
There are various immune profiles of dually infected
patients with chronic hepatitis, and their immune profiles
have a bearing on the choice of treatment. One possibility
is dually active HBV and HCV, in which patients have
detectable serum HBV DNA and HCV RNA. It stands to
reason that these patients are at highest risk of progression
to cirrhosis and decompensated liver disease, and there-
fore, should be considered for treatment. Another possi-
bility is active HCV infection (positive HCV RNA) in the
setting of an inactive HBsAg carrier. Such patients behave
similar to patients with HCV monoinfection, and likely
exhibit HCV viral suppression of HBV activity. Another
possibility is active HBV infection in patients with inactive
or prior HCV infection (HBV DNA positive/HBeAg posi-
tive/HCV RNA negative/anti-HCV positive). This immune
profile is less common, and indicates HBV suppression of
HCV. The various immune profiles have significance in
regards to treatment options as will be discussed below
(Table 3).
Cirrhosis
Coinfected patients have higher rates of cirrhosis with
decompensation. One cross-sectional study found higher
rates of cirrhosis (44% vs. 21%) and decompensated liver
disease (24% vs. 6%) in coinfected patients compared to
patients with chronic HBV monoinfection [16]. Moreo-
ver, HBV replication in coinfected patients (detectable
serum HBV DNA) has been correlated with higher rates of
cirrhosis, Knodell score, piecemeal necrosis and fibrosis
[29]. A Saudi Arabian study found that coinfected patients
(compared to HCV monoinfected patients) had more
decompensated liver disease with a higher proportion of
cirrhosis (95% vs. 48.5%) and Child-Pugh class C (37%
vs. 0%) [42].
Hepatocellular Carcinoma
Coinfection with HBV and HCV has been shown in many
case-control studies to correlate with an increased risk of
developing HCC [4,42]. One study found a rate of HCC in
coinfected patients of 63% compared to 15% in HCV
monoinfection [42]. Benvegnu et al. [1] conducted a pro-
spective study of 290 cirrhotic patients and found that
coinfection (detectable anti-HCV and HBsAg) was an
independent predictor for development of HCC in a uni-
variate and multivariate analysis (p < 0.02, p < 0.05
respectively). A subsequent longitudinal study confirmed
these results, and reported a rate of incidence of HCC (per
100 person years) of 6.4 in dually infected patients, com-
pared to 2.0 in HBV and 3.7 in HCV monoinfected
patients, and a 45% cumulative risk of developing HCC at
10 years in coinfected patients, compared with 16% and
28% in HBV and HCV monoinfected controls [2]. Simi-
larly, A South African study reported an 83-fold increased
for developing HCC among coinfected patients compared
to patients without hepatitis B or C [43]. Because of the
likely increased risk of developing HCC, coinfected
patients should receive regular 6-month and possible
more frequent screening with ultrasound of the liver and
serum alfa-fetoprotein levels.
Table 2: AASLD Recommendations for Treatment of Chronic Hepatitis C
Therapy Widely Accepted Therapy Contraindicated Treatment Recommendations
• Detectable HCV RNA
• 18 years of age or older
• Elevated ALT
• Liver biopsy showing chronic hepatitis with 
significant fibrosis
• Compensated liver disease (total serum 
bilirubin <1.5 g/dL; INR <1.5; albumin >3.4 g/
dL; platelet count >75,000 k/mm3; and no 
evidence of hepatic encephalopathy or ascites)
• Acceptable hematological and biochemical 
indices (hemoglobin >13 g/dL for men and >12 
g/dL for women; neutrophil count >1.5 k/mm3; 
creatinine <1.5 mg/dL)
• Not treated previously for HCV infection
• History of depression but well controlled
• Patient willing to be treated and to conform 
to treatment requirements
• Major, uncontrolled depression
• Renal, heart, or lung transplant recipient
• Autoimmune hepatitis or other condition 
known to be exacerbated by interferon and 
ribavirin
• Untreated hyperthyroidism
• Pregnant or unwilling/unable to comply with 
adequate contraception
• Severe concurrent disease such as severe 
hypertension, heart failure, significant coronary 
artery disease, poorly controlled diabetes, 
obstructive pulmonary disease
• Under 3 years of age
• Known hypersensitivity to drugs used to treat 
HCV
Genotype 1 HCV infection:
• Peginterferon plus ribavirin (1000–1200 mg 
daily) for 48 weeks
• Treatment may be discontinued in patients 
who do not achieve an EVR at 12 weeks
• In patients who have negative HCV RNA at 
48 weeks, retest HCV RNA at 72 weeks to 
confirm SVR
Genotype 2 or Genotype 3 infection:
• Peginterferon plus ribavirin (800 mg daily) for 
24 weeks
• In patients who have negative HCV RNA at 
24 weeks, retest HCV RNA at 48 weeks to 
confirm SVR
Abbreviations: INR: international normalized ratio; EVR: early virologic response; SVR: sustained virologic response. Source: Strader DB, Wright T, 
Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.Annals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
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Treatment
General Principles
Well established treatment guidelines exist for patients
with chronic hepatitis B and chronic hepatitis C [44-49].
In regards to HBV infection, the Asian-Pacific Association
for the Study of the Liver (APASL), the European Associa-
tion for the Study of the Liver (EASL) and the American
Association for the Study of Liver Diseases (AASLD) rec-
ommend treating patients who have moderate to severe
chronic hepatitis as evidenced by >2-fold elevation of ALT
levels or significant findings on liver biopsy associated
with HBV DNA >105 copies/mL. Patients may have detect-
able HBeAg associated with wild type virus or HBeAg-neg-
ative from infection with the precore or core promoter
mutant virus. Currently licensed drugs for chronic hepati-
tis B in the United States include interferon alfa-2b, lami-
vudine, adefovir, entecavir, and peginterferon alfa-2a.
Patients with fulminant hepatitis and decompensated cir-
rhosis are not likely to respond to antiviral agents and are
candidates for liver transplantation (Table 1). Patients
with chronic hepatitis C with detectable serum HCV RNA
are candidates for 24 to 48 weeks of antiviral therapy
based on genotype. Currently standard treatment for hep-
atitis C is peginterferon alfa-2a or 2b plus ribavirin. As
with chronic hepatitis B, patients with decompensated
liver disease or fulminant hepatitis (rare with acute hepa-
titis C) are candidates for liver transplantation (Table 2).
There is no currently established standard of care for
patients who are coinfected with HBV and HCV. In gen-
eral, the same treatment criteria should be applied to
patients who are HBC/HCV dually infected as are applied
to monoinfected patients (Tables 1 and 2). Initiation of
treatment, as with both HBV and HCV, is recommended
in patients with active chronic hepatitis or cirrhosis prior
to decompensation (Figure 1). Given the complex interac-
tion of HBV and HCV both with each other and with the
immune system, care must be taken to select the most
appropriate antiviral regimen based on serologic markers
and levels of viremia. Because of its activity against both
viruses, interferon therapy has been the most studied. The
published data on the antiviral treatment of HBV and
HCV coinfection is reviewed in the following discussion
and summarized in Table 4.
Interferon
Interferon is an immunomodulating medication with
antiviral and antiproliferative effects and has been well
studied in patients with chronic viral hepatitis. Interferon
alpha (IFNα) is an approved treatment for both chronic
hepatitis B and C. In appropriately selected patients with
hepatitis C, interferon treatment led to sustained virolog-
ical response (SVR), i.e. negative HCV RNA 6 months fol-
lowing completion of treatment, in approximately 10% of
HCV patients. These results are improved when IFN is
used with ribavirin (SVR up to 43%), and when
peginterferon plus ribavirin is used (SVR up to 56%) [45].
In chronic HBV infection, IFN is indicated for patients
with chronic hepatitis with elevated ALT and HBV DNA
levels, and has the benefits of a lack of resistance and a
durable response in those who respond to therapy. In
studies of HBV patients, interferon is effective in roughly
35% of patients [50]. Peginterferon has also recently
shown promise in treatment of hepatitis B [51], and
peginterferon alfa-2a was recently licensed in the United
States.
IFN has been the most studied agent in treatment of coin-
fected patients because of the wealth of experience with
this agent in viral hepatitis and its proven activity against
both viruses. One of the first case reports of successful
treatment with IFN of a coinfected patient (resulting in
HBeAg loss and a SVR of HCV infection) was published by
Burt et al. in 1993 [52]. Several case series were subse-
quently reported. In 1995, Géhénot et al. [53] studied 16
patients with histologically proven chronic hepatitis with
Table 3: Immune Profiles of Patients with Chronic Hepatitis due to Coinfection, and Suggested Treatments Based on Published Trials
Immune profile HBV DNA HBsAg HBeAg HCV RNA Anti-HCV Possible treatments [ref]
Dually active + +/- +/- + + IFN alone [54]
IFN + ribavirin [57-59]
IFN + lamivudine [61]
Active HCV in HBV carrier - + - + + IFN alone [23, 53, 55]
IFN + ribavirin [57-59]
Active HBV in chronic HCV + - - + + IFN alone [10]
IFN + lamivudine [61]
Silent HBV + - - +/- + IFN alone [10]
IFN + lamivudine [61]
Abbreviations: HCV = hepatitis C virus; HBV = hepatitis B virus; DNA = deoxyribonucleic acid; RNA = ribonucleic acid; HBsAg = Hepatitis B 
surface antigen; HBeAg = Hepatitis B e antigen; Anti-HCV = antibody to hepatitis C virus; IFN = interferonAnnals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
Page 7 of 12
(page number not for citation purposes)
positive anti-HCV, HCV RNA, HBsAg, and anti-HBe (HBV
DNA negative), compared to patients with chronic HCV
infection alone. Treatment consisted of IFNα at 3 million
units (MU) thrice weekly (TIW) for 6 months. A similar
rate of sustained biochemical response (normal ALT at 6
months following treatment; SBR) was achieved in coin-
fected patients compared to controls (19 vs. 21%). Two
patients treated with IFN seroconverted to HBsAg nega-
tive. This study demonstrated that comparable results
could be obtained with interferon in coinfected patients
who do not have evidence of HBV replication. A subse-
quent study by Weltman et al. [3] of 8 coinfected patients
Table 4: Medication Trials in Hepatitis B and Hepatitis C Coinfected Patients
Author 
[Ref]
Patients # Treatment × 
Duration
HCV SVR HBV DNA 
negative
HBsAg loss HBeAg loss SBR
Interferon Trials
Gehenot [53] Anti-HCV+
HCV RNA+
HBsAg+
HBV DNA-
16 IFNα 3 MU TIW 
× 6 mo
N/A N/A 12.5% N/A 19%
Weltman [3] Anti-HCV+
HBsAg+
8I F N α 3 MU TIW 
× 6 mo
N/A N/A 12.5% N/A 12.5%
Guptan [54] Anti-HCV+
HCV RNA+
HBsAg+
HBV DNA+
7I F N α 6 MU TIW 
× 6 mo
29% 86% 28.6% 100% 0%
Villa [55] Anti-HCV+
HCV RNA+
HBsAg+
30 IFNα 9 MU TIW 
× 6 mo or 6 MU 
TIW × 6 mo
16.7% (31%)* 66.7% 
(100%)*
3% N/A 20% (37.5%)*
Utili [23] Anti-HCV+
HBeAg ±
HCV RNA ±
16 IFNα 5 MU TIW 
× 12 mo
43.8% N/A N/A 15.4% 50%
Zignego [10] Anti-HCV+
HBV DNA+
HBsAg-
14 IFNα 3 MU TIW 
× 12 mo
0% 0% N/A N/A 0%
Liaw [56] Anti-HCV+
HBV DNA+
HBeAg+
15 IFNα 9 MU TIW 
× 14 wk or 4–6 
MU TIW × 12 wk
0% 6.7% 6.7% 6.7% 6.7%
Interferon plus ribavirin trials
Liu [57] Anti-HCV+
HCV RNA+
HBsAg+
21 IFNα 6 MU TIW 
× 3 mo + 3 MU 
TIW × 3 mo + 
ribavirin × 6 mo
43% 35% 0% 100% 43%
Hung [58] Anti-HCV+
HCV RNA+
HBsAg+
36 IFNα 3–5 MU 
TIW + ribavirin × 
6 mo
69% 11% 0% 0% 56%
Chuang [59] Anti-HCV+
HCV RNA+
HBsAg+
42 IFNα 6 MU TIW 
+ ribavirin × 6 mo
69% 31.3% 14.3% 50% 54.8%
Interferon plus lamivudine trials
Marrone [61] HBeAg+
HBV DNA+
HCV RNA+
8 IFN 5 MU TIW × 
12 mo + 
lamivudine × 18 
mo
50% 37.5% 0% 37.5% 50%
*9 MU arm. Abbreviations: # = number of patients; Ref = reference; SVR = sustained virologic response; SBR = sustained biochemical response; 
HCV = hepatitis C virus; HBV = hepatitis B virus; Anti-HCV = Antibody to hepatitis C virus; HBsAg = hepatitis B surface antigen; HBeAg = hepatitis 
B e antigen; mo = month; wk = week; TIW = thrice weekly; IFNα = interferon alfaAnnals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
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treated with the same regimen (IFN alfa-2b 3 MU TIW for
6 months) reported similar results, with 1 patient experi-
encing SBR (12.5%). The patient with SBR seroconverted
at 6 months to HBsAg negative/anti-HBs positive. An
Indian study of 7 dually infected patients (HBsAg, HBV
DNA, anti-HCV, HCV RNA positive) used a higher dose of
IFN alfa-2b (6 MU) for 6 months [54]. After 6 months fol-
low-up, the authors reported 100% of patients lost HBV
DNA, 100% of HBeAg-positive patients lost HBeAg (3/3),
and 29% lost HCV RNA (i.e. SVR = 29%). Utili et al. [23]
studied a cohort of 32 HBV/HCV coinfected patients, 16
of whom received IFN treatment (5 MU TIW for 12
months). They report an overall SVR rate of 43.8% for
HCV infection, and this rate was increased in patients who
were HBeAg negative (66.7%). Loss of HBeAg occurred in
2 of 13 patients (15.4%).
Villa et al. [55] conducted a larger prospective rand-
omized trial of 30 patients with HBV/HCV coinfection
(HBsAg-positive, Anti-HCV-positive, HCV RNA-positive),
in which patients received either 6 or 9 MU IFN-α TIW for
6 months. This study found that higher dose IFN was
more effective in inducing clearance of HCV RNA (31.2%
vs. 0%, p = 0.045) and HBV DNA (100% vs. 0%), as well
as inducing a SBR (37.5% vs. 0%, p = 0.019) compared to
the lower dose. Histological scores were better in patients
in the high-dose arm as well. This was the first study to
suggest that higher doses of IFN may be indicated in coin-
fected patients.
Several studies have reported detectable HBV DNA in
patients with chronic hepatitis C but negative HBsAg. This
so-called "serologically silent" HBV infection or "inappar-
ent coinfection" has been correlated with impaired
response to IFN treatment. Zignego et al. [10] reported sig-
nificantly worsened results in 14 chronically infected HCV
patients with inapparent HBV coinfection (anti-HCV-pos-
itive, HBV DNA-positive, HBsAg-negative). Patients were
treated with IFN alfa-2a TIW for 12 months. Four out of
14 patients had normal ALT levels at the end of therapy
(28%), but all had relapsed within 6 month post-treat-
ment, and thus none had a SVR. Fukuda et al. [14] also
found that silent HBV infection was associated with
higher ALT levels, greater histological activity scores and
poor efficacy of IFN treatment. Some have proposed that
the impaired response to IFN in such patients may be due
to HBV-mediated down-regulation of intrahepatic IFN
receptor gene expression [15].
A hepatitis C flare has been described in a coinfected
patient who had HBeAg/HBV DNA clearance in response
to IFN [56]. For this reason, some investigators have
raised concern that IFN treatment of coinfected patients
carries the risk of a severe hepatitis flare if the suppressive
effect of one virus is removed, thereby allowing the other
virus to become active.
Though there have been no published studies of the use of
peginterferon (peg-IFN) in coinfected patients, the use of
this agent will likely replace standard interferon in treat-
ment of HBV/HCV coinfection, as peginterferon is now
the standard of care for the treatment of chronic hepatitis
C, and has recently been approved for the treatment of
chronic hepatitis B.
Interferon plus Ribavirin
Several groups have published studies addressing treat-
ment of coinfected patients with antiviral combination
therapy with IFNα plus ribavirin. Liu et al. [57] treated 24
dually infected patients (HBsAg positive/anti-HCV posi-
tive) with IFN alfa-2a (6 MU TIW for 12 weeks followed
by 3 MU TIW for 12 weeks), concurrently with ribavirin
1200 mg daily for 24 weeks. Seventeen patients were pos-
itive for both HBV DNA and HCV RNA. Results showed a
SVR rate of 43% for clearance of HCV RNA, compared to
60% in similarly treated HCV monoinfected controls. Six
of 17 patients with detectable HBV DNA at baseline had
disappearance of HBV DNA at the end of treatment per-
sisting to 24 weeks post-treatment (35%). A SBR rate of
43% was reported. These results demonstrate the effec-
tiveness of combined IFN and ribavirin in coinfected
patients, with a rate of SVR and SBR comparable to HCV
monoinfected patients.
Hung et al. [58] treated 36 patients with HBV/HCV coin-
fection (HBsAg-positive/anti-HCV-positive/HCV RNA-
positive) with combination IFN alfa-2b (3 or 5 MU TIW)
and ribavirin (800–1200 mg/day) for 24 weeks. This
study reported a SVR rate of 69% and SBR rate of 56%.
Loss of HBV DNA was found in 2 of 18 patients with HBV
DNA detected at baseline (11%). Interestingly, 53% of
patients with negative HBV DNA at baseline had reactiva-
tion of HBV DNA at the 48 weeks of follow-up.
Chuang et al. [59] studied combination therapy with
high-dose IFN alfa-2b (6 MU 3 times weekly for 24 weeks)
and ribavirin (1000–1200 mg daily for 24 weeks) in 42
coinfected patients, compared to a control group of HCV
monoinfected patients. The investigators found compara-
ble rates of SVR in HCV coinfected (69.0%) and monoin-
fected (67.2%) patients (IFN naïve). Disappearance of
HBV DNA occurred in 5 of 16 (31%) patients with posi-
tive HBV DNA at baseline. Viral interaction was evident,
in that coinfected patients who achieved a SVR (compared
HCV nonresponders) were less likely to achieve HBV DNA
clearance (8.3% vs. 100%), and more likely to have reac-
tivation of HBV (58.8% vs. 12.5%) or HBV flares (44.8%
vs. 8.3%). Of the patients who cleared HBV DNA, 4 of 5
were patients who did not achieve a SVR with undetecta-Annals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
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ble HCV RNA following combination therapy. Nonethe-
less, the high SVR rate for HCV infection in this
population provides further evidence that IFN plus ribavi-
rin combination therapy can be effective in coinfected
patients, especially those who have active HCV
replication.
As described in the above studies, successful treatment of
chronic HCV infection may correlate to HBV reactivation
and flaring. Yalcin et al. reported a severe hepatitis B flare
in a patient with HBV/HCV coinfection (HBV DNA-nega-
tive) undergoing treatment with IFN and ribavirin [60].
This patient's hepatitis improved after discontinuation of
therapy, but a relapse of HCV infection with rapid pro-
gression to cirrhosis occurred thereafter. Clinicians must
exercise caution when treating coinfected patients with
combination IFN plus ribavirin given this risk of HBV
reactivation.
Interferon plus Lamivudine
One study of lamivudine therapy in addition to IFN for
coinfected patients has been published by Marrone et al
[61]. Eight patients with dually active HBV and HCV
(HBeAg-positive/HBV DNA-positive/HCV RNA-positive)
were treated with 5 MU of IFN and lamivudine 100 mg/
day for 12 months followed by lamivudine alone for 6
months. Three patients had clearance of HBeAg, 3 had
clearance of HBV DNA (37.5%), and post-treatment ALT
levels normalized in 4 of 8 (50%) treated patients. Four
patients (50%) also had clearance of HCV RNA that was
persistent at 12 months post-treatment (i.e. HCV SVR =
50%). This initial study suggests that the addition of lam-
ivudine to IFN may be effective in coinfected patients with
chronic hepatitis C and active HBV replication. Further
studies on this combination therapy in larger groups of
patients must be performed in order to confirm these
results.
Adefovir and Entecavir
There have been no published studies regarding treatment
of coinfected patients with the newer agents adefovir and
entecavir. However, these agents may be useful, particu-
larly in patients with HBV-dominant disease. Studies need
to be performed using these agents before they can be rec-
ommended for routine usage.
Transplantation
The United Network of Organ Sharing (UNOS) reported
that 14 patients were transplanted for combined hepatitis
B and C in the United States in 2004, and 434 patients
have been transplanted for this indication since 1988
[62]. There are limited data on the post-transplant course
of such patients. One small study by Huang et al. [63]
reported results of 19 patients with coinfection (either
acquired or persistent) following transplantation. This
study found that survival of patients with HBV monoin-
fection was worse than that of dually infected patients,
suggesting a possible beneficial role of HCV in the immu-
nosuppressed post-transplant population. Further studies
are needed to clarify the clinical course and optimal man-
agement of coinfected post-transplant patients.
Special Populations
Triple Infection with HBV, HCV and Hepatitis Delta Virus
Hepatitis delta virus (HDV) infects only patients with pre-
existing HBV infection. Triple hepatotropic viral infec-
tions with HBV, HCV and HDV can result in more severe
hepatitis, and therefore compel the clinician to offer treat-
ment [8]. Few studies have been published regarding
treatment of patients with triple hepatitis virus infection.
Weltman et al. [3] studied 7 patients with triple infection
who received IFN therapy. One patient had a reported
SBR, and 2 patients were withdrawn from treatment due
to side effects. Interferon treatment is a reasonable recom-
mendation despite the paucity of data to support its use.
Further studies are needed on such patients to determine
optimal therapy.
Triple Infection with HBV, HCV and Human Immunodeficiency Virus
Triple infection with HBV, HCV and the human immuno-
deficiency virus (HIV) is a complex clinical scenario, due
to the interaction of HBV and HCV, and the impact of HIV
on the immune system. In addition, a majority of patients
with HIV/HCV coinfection are infected with HCV geno-
type 1, decreasing their response to interferon therapy and
thereby rendering treatment more difficult [64]. Further-
more, HCV/HIV coinfection has been shown to result in
more severe liver disease and an increased risk of liver dis-
ease-related death [65]. No standard of care exists for such
patients, and treatment must be individualized and coor-
dinated with an HIV specialist. Infection of HIV must be
controlled before treatment of viral hepatitis can be con-
sidered [66]. Few studies have been performed on treat-
ment of patients with triple infection, so treatment
algorithms are often extrapolated from results of trials of
patients with either HBV/HIV or HCV/HIV coinfection.
IFN alone is associated with a SVR rate of approximately
17% in HCV/HIV coinfected patients, and this rate
increases to 25% with the addition of ribavirin [67]. Lam-
ivudine has been used in HBV/HIV coinfected patients,
but is associated with a high rate of resistance [68]. There
is promise for the use of newer agents such as adefovir,
entecavir, tenofovir, and emtricitabine, but no studies
have corroborated their utility in this population [66].
Summary of Treatment Recommendations
Thorough serologic and virologic testing is required in
dually infected patients prior to consideration of therapy.
Assessment of the "dominant" virus is helpful in deter-
mining a treatment strategy. Caution must be taken withAnnals of Clinical Microbiology and Antimicrobials 2005, 4:13 http://www.ann-clinmicrob.com/content/4/1/13
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treatment of coinfected individuals, as exacerbations of
liver disease after initiation of therapy have been
described, likely due to loss of viral suppression from the
successfully treated dominant virus. Patients are candi-
dates for therapy if they meet the inclusion criteria for
standard treatment guidelines for either HBV or HCV
monoinfection (Tables 1 and 2). In coinfected patients
with HCV dominant disease, IFN plus ribavirin treatment
has been well studied and has proven efficacy. In patients
with HBV dominant disease, IFN with or without lamivu-
dine is a reasonable option. Further studies of other HBV
treatment agents such as adefovir and entecavir are
needed before these agents can be routinely recom-
mended, though they may be used on a case by case basis.
In addition, future studies are needed to assess the effec-
tiveness of peginterferon as well as triple therapy with
lamivudine, IFN, and ribavirin in coinfected patients,
though peginterferon should generally be used in place of
standard interferon in coinfected patients given its proven
efficacy in HBV and HCV monoinfected patients. Referral
to a transplant center is indicated for patients with decom-
pensated cirrhosis, fulminant hepatitis, or HCC in appro-
priate patients. In patients with triple HCV/HBV/HDV
infections, few treatment studies have been published, but
IFN is a reasonable treatment. Patients who have triple
infection with HIV/HBV/HCV should have their care coor-
dinated with an HIV specialist.
Conclusion
Coinfection with HBV and HCV is not uncommon, espe-
cially within areas of high prevalence of hepatitis B. Dual
infections present unique management challenges given
the complex interaction of HBV and HCV, and the pro-
pensity for developing more severe liver disease. Treat-
ment options mostly include IFN with or without
lamivudine or ribavirin. Treatment decisions should be
made based upon the determination of the "dominant"
hepatitis virus. Caution must be exercised in treating
coinfected patients, as flares of the untreated virus may
occur. No standard of care has been established for treat-
ment of coinfected patients, and larger randomized, con-
trolled trials are needed to clarify the optimal treatment
for such patients and the role of newer antiviral agents.
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